research Activation of AR Sensitizes Breast Carcinomas to NVP-BEZ235's Therapeutic Effect Mediated by PTEN and KLLN Upregulation
Breast cancer treatments work better with AR activation, improving results and reducing side effects.
Search
for
Sort by
Research
480-510 / 1000+ resultsresearch Scarring alopecia and nail loss in a patient with epidermolysis bullosa acquisita
Untreated epidermolysis bullosa acquisita can cause total hair and nail loss.
research Cytokine Engineering Approaches for Regenerative Medicine
Engineered cytokines show promise for improving tissue healing and safety in regenerative medicine.
research Repigmentation of hair following adalimumab therapy
A patient's grey hair regained color during treatment with adalimumab.
research Two Phase 3 Trials of Baricitinib for Alopecia Areata
Baricitinib was effective in treating alopecia areata in two major trials.
research Successful Treatment of Adalimumab-Induced Paradoxical Skin Reactions in Pustulotic Arthro-Osteitis With Guselkumab
Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.
research Baricitinib Attenuates IFN-γ and Polyinosinic:polycytidylic Acid‒Induced Mitochondrial Damage and Inflammasome Activation in Human Keratinocytes
Baricitinib reduces inflammation and mitochondrial damage in skin cells.
research Pembrolizumab-Induced Autoimmune Hepatitis
Pembrolizumab can cause serious liver issues, requiring close monitoring and early treatment.
research Multiple sclerosis disease-modifying therapies: adverse effect surveillance and management
The document concludes that managing side effects of MS therapies is crucial for treatment success and patient adherence.
research 33766 Efficacy of baricitinib in patients with various degrees of alopecia areata severity: Results from BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
research Baseline methotrexate does not impact the incidence of infliximab infusion reactions: Results from a Canadian real-world treatment registry
Clofazimine effectively treated ashy dermatosis in a patient.
research Provenge is Talk of GU Malignancies Congress
Provenge extends prostate cancer survival by about 4 months.
research Rash from EGFR inhibitors: Opportunities and challenges for palliation
EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.
research 34007 Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials
Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
research Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study
Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.
research Enzyme Replacement Therapy Ameliorates Multiple Symptoms of Murine Homocystinuria
Enzyme replacement therapy improved multiple symptoms of homocystinuria in mice.
research Therapeutic Burden as Predictor of Response to Baricitinib for Alopecia Areata in Real Life: Prospective Study
Patients with fewer past treatments for alopecia areata respond better to baricitinib.
research Novel Fish Oil-based Bigel System for Controlled Drug Delivery and its Influence on Immunomodulatory Activity of Imiquimod Against Skin Cancer
The fish oil-based gel with imiquimod improves skin cancer treatment and reduces inflammation.
research Retinoids and Phototherapy for Psoriasis
Retinoids and narrowband UVB phototherapy are effective for treating psoriasis and can reduce treatment time when used together.
research Brazilian Experience of the Treatment of Alopecia Universalis with the Novel Antirheumatic Therapy Tofacitinib: A Case Series
Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.
research Efficacy of JAK 1/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus
Baricitinib might help treat hair loss in lupus patients, but more research is needed.
research 49690 Long-term efficacy of baricitinib in alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2
Baricitinib maintains significant hair regrowth in severe alopecia areata over three years.
research Severe cutaneous adverse reactions to drugs
Some drugs can cause rare but potentially deadly skin reactions, and early treatment and avoiding the drug again are key.
research 0873 Modeling junctional epidermolysis bullosa using tissue-engineered skin substitutes
Tissue-engineered skin substitutes can model junctional epidermolysis bullosa and may help develop gene therapy.
research Résultats à long-terme d’un implant acétabulaire monobloc en métal trabéculaire. Essai clinique randomisé à 10 ans de recul minimum
research TWEAK-conjugated selenoviologen as a novel photosensitizer for selective wound accumulation and synergistic healing of drug-resistant bacterial infections
SeV-Tp speeds up healing of drug-resistant infections by targeting wounds and killing bacteria with light activation.
research Contact immunotherapy-induced Renbök phenomenon in a patient with alopecia areata and psoriasis vulgaris
Contact immunotherapy helped hair regrow in a patient with both alopecia and psoriasis.
research An overview of the more significant therapeutic effects of TECAR therapy
TECAR therapy helps with pain relief, reduces inflammation, relaxes muscles, heals tissues, and is safe and effective for many conditions.
research Dupilumab in the treatment of severe atopic dermatitis refractory to systemic immunosuppression: case report
Dupilumab improved severe atopic dermatitis in a patient who didn't respond to other treatments.
research Toxic epidermal necrolysis due to cephalexin
A woman developed a severe skin reaction called toxic epidermal necrolysis after taking the antibiotic cephalexin.